chenodeoxycholic acid has been researched along with Insulin Sensitivity in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 15 (83.33) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Costantino, G; Fiorucci, S; Pellicciari, R | 1 |
| Adorini, L; Brescia, P; Galbiati, M; Invernizzi, P; Mileti, E; Mouries, J; Penna, G; Rescigno, M; Silvestri, A; Sorribas, M; Spadoni, I; Wiest, R | 1 |
| Serfaty, L | 1 |
| He, Y; Huang, QF; Li, ZW; Tang, WL; Wang, ZW; Wu, S; Yang, YL; Zhou, HW; Zhou, WW; Zhou, ZY | 1 |
| Kim, W | 1 |
| Aguilera, V; Ampuero, J; Bellido, F; Romero-Gómez, M; Sánchez-Torrijos, Y | 1 |
| Briand, F; Brousseau, E; Burcelin, R; Quinsat, M; Sulpice, T | 1 |
| Asakawa, M; Goto, T; Itoh, M; Kai, T; Kanai, S; Ogawa, Y; Sakai, T; Shirakawa, I; Suganami, T; Yoneyama, T | 1 |
| Adorini, L; Bellafante, E; Fan, HM; Jansen, E; Jones, P; Marchesi, JR; Marschall, HU; McDonald, JAK; McIlvride, S; Nikolova, V; Shapiro, D; Wahlström, A; Williamson, C | 1 |
| Agrawal, R; Anderssohn, M; Atzler, D; Böger, RH; Cooke, JP; Ghebremariam, YT; Higgins, JP; Johnson, CL; Lee, JC; Patterson, AJ; Yamada, K | 1 |
| Adorini, L; Castelloe, E; Clopton, P; Dillon, P; Henry, RR; Kipnes, M; Marschall, HU; Morrow, L; Mudaliar, S; Pruzanski, M; Sanyal, AJ; Sciacca, CI; Shapiro, D | 1 |
| Sanyal, AJ | 1 |
| James, J; Roy, D; Shihabudeen, MS; Thirumurugan, K | 1 |
| Hameed, B; Terrault, N | 1 |
| Dufour, JF; Perazzo, H | 1 |
| Cipriani, S; Fiorucci, S; Mencarelli, A; Palladino, G | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Distrutti, E; Fiorucci, S; Mencarelli, A; Palladino, G; Renga, B | 1 |
| Boverhof, R; Jonkers, IJ; Kuipers, F; Masclee, AA; Princen, HM; Romijn, JA; Smelt, AH; Stellaard, F | 1 |
7 review(s) available for chenodeoxycholic acid and Insulin Sensitivity
| Article | Year |
|---|---|
Farnesoid X receptor: from structure to potential clinical applications.
Topics: Animals; Bile Acids and Salts; Binding Sites; Cardiovascular Diseases; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Insulin Resistance; Ligands; Models, Molecular; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2005 |
[Pharmacological treatment of NASH].
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Cytoprotection; Glucagon-Like Peptide 1; Humans; Imidazoles; Insulin Resistance; Metformin; Non-alcoholic Fatty Liver Disease; Patient Selection; Pharmaceutical Preparations; Propionates; Sulfoxides; Thiazolidinediones | 2019 |
[Treatment Options in Non-alcoholic Fatty Liver Disease].
Topics: Antibodies, Monoclonal, Humanized; Chalcones; Chenodeoxycholic Acid; Humans; Insulin Resistance; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR gamma; Propionates; Receptors, Cytoplasmic and Nuclear; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
New therapeutic perspectives in non-alcoholic steatohepatitis.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Clinical Trials as Topic; Combined Modality Therapy; Diet, Mediterranean; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Dyslipidemias; Endoscopy; Exercise Therapy; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Humans; Insulin Resistance; MAP Kinase Kinase Kinase 5; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Weight Loss | 2018 |
Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
Topics: Animals; Atherosclerosis; Chenodeoxycholic Acid; Humans; Insulin Resistance; Lipid Metabolism; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear | 2015 |
Emerging Therapies for Nonalcoholic Fatty Liver Disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antioxidants; Caspase Inhibitors; Chenodeoxycholic Acid; Cholic Acids; Fatty Acids, Omega-3; Humans; Incretins; Insulin Resistance; Liraglutide; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Pectins; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
The therapeutic landscape of non-alcoholic steatohepatitis.
Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Propionates; Randomized Controlled Trials as Topic; Thiazolidinediones; Vitamin E; Weight Loss | 2017 |
2 trial(s) available for chenodeoxycholic acid and Insulin Sensitivity
| Article | Year |
|---|---|
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Topics: Adult; Aged; Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2013 |
Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
Topics: Bezafibrate; Bile Acids and Salts; Blood Glucose; Body Mass Index; Chenodeoxycholic Acid; Cholesterol; Cholic Acid; Clofibric Acid; Cross-Over Studies; Fasting; Fish Oils; Gallstones; Humans; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Triglycerides | 2006 |
9 other study(ies) available for chenodeoxycholic acid and Insulin Sensitivity
| Article | Year |
|---|---|
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Topics: Animals; Bacterial Translocation; Capillary Permeability; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Insulin Resistance; Intestinal Mucosa; Liver; Mice; Non-alcoholic Fatty Liver Disease; Protective Agents | 2019 |
Intestinal Flora is a Key Factor in Insulin Resistance and Contributes to the Development of Polycystic Ovary Syndrome.
Topics: Animals; Bacteroides; Biomarkers; Case-Control Studies; Chenodeoxycholic Acid; Female; Fibroblast Growth Factors; Gastrointestinal Microbiome; Glucose; Glucose Tolerance Test; Humans; Insulin Resistance; Letrozole; Metabolomics; Mice; Mice, Inbred C57BL; Phenotype; Polycystic Ovary Syndrome; Receptors, Cytoplasmic and Nuclear; RNA, Ribosomal, 16S; Sequence Analysis, DNA | 2021 |
Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
Topics: Animals; Body Weight; CD36 Antigens; Chenodeoxycholic Acid; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Diet; Disease Models, Animal; Dyslipidemias; Gene Expression Regulation; Insulin Resistance; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Receptors, LDL | 2018 |
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Topics: Animals; Body Weight; Cell Death; Chenodeoxycholic Acid; Cytoprotection; Disease Models, Animal; Disease Progression; Gene Knockout Techniques; Hepatocytes; Insulin Resistance; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Receptor, Melanocortin, Type 4; Tumor Suppressor Protein p53 | 2018 |
Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.
Topics: Animals; Blood Glucose; Chenodeoxycholic Acid; Diabetes, Gestational; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Glucose Intolerance; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Pregnancy; Pregnancy Complications | 2019 |
FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats.
Topics: Amidohydrolases; Animals; Blood Pressure; Cardiomegaly; Chenodeoxycholic Acid; Diet; Gene Expression Regulation; Hypertension; Insulin Resistance; Kidney; Kidney Function Tests; Liver; Male; Nitric Oxide; Organ Size; Rats; Receptors, Cytoplasmic and Nuclear; Sodium Chloride, Dietary | 2013 |
Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance.
Topics: 3T3-L1 Cells; Adipokines; Adipose Tissue; Animals; Chenodeoxycholic Acid; Gene Expression Regulation; Inflammation; Inflammation Mediators; Insulin Resistance; Male; Mice; Palmitic Acid; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear | 2015 |
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Topics: Animals; Chenodeoxycholic Acid; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver; Gene Expression Regulation; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Lipids; Liver; Male; Muscle, Skeletal; Obesity; Phosphorylation; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors | 2010 |
FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Bile Acids and Salts; Blood Glucose; Cardiovascular Diseases; Chenodeoxycholic Acid; Dyslipidemias; Fibrosis; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Isoxazoles; Lipid Metabolism; Liver; Myocardium; Obesity; PPAR alpha; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Risk Factors; RNA, Messenger; Triglycerides | 2013 |